Rejuvel Bio-Sciences (NUUU) 10-K/A 17 Apr 15 2014 FY Annual report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Apr. 15, 2015	Jun. 30, 2014
Document And Entity Information
Entity Registrant Name	Technology Applications International Corp
Entity Central Index Key	1481427
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$18,380,871
Entity Common Stock, Shares Outstanding		50,118,963
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets
Cash and cash equivalents	$39,501	$4,891
Inventories	4,831	70,862
Deposits	7,000	7,000
Other current assets	1,722	1,909
Total current assets	53,053	84,662
Intangible assets, net	15,859	1,940
Machinery and equipment, net	32,092	19,371
Other Assets
Security deposits	3,725	0
Total assets	104,728	105,973
Liabilities
Accounts payable and accrued expenses	458,783	344,415
Advances from affiliate	270,747	237,480
Loan from affiliate	157,068	77,401
Convertible debentures (net of debt discount of $0 and $75,902 respectively)	0	198,099
Deferred rent	2,713	0
Derivative liability	48,851	349,940
Total current liabilities	938,162	1,207,335
Total liabilities	938,162	1,207,335
Shareholders' deficit
Preferred stock, par value, $0.001 per share, 50,000,000 shares authorized, none issued or outstanding	0	0
Common stock, par value $0.001 par value, 300,000,000 shares authorized, 50,138,493 and 117,348,000 shares issued and outstanding at December 31, 2014 and December 31, 2013, respectively.	50,138	117,348
Additional paid in capital	1,274,202	586,199
Accumulated deficit	-2,157,774	-1,804,909
Total shareholders' deficit	-833,434	-1,101,362
Total liabilities and shareholders' deficit	$104,728	$105,973

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	50,138,493	117,348,000
Common stock, shares outstanding	50,138,493	117,348,000
Discount on convertible debentures	$0	$75,902

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Revenues	$94,096	$51,559
Cost of revenues	83,304	26,805
Gross profit	10,792	24,754
Expenses
General and administrative	697,997	554,460
Loss From Operation	-68,705	-529,706
Other income (expense)
Gain on derivative valuation	700,279	64,232
Derivative expense	-267,253	0
Gain on forgiveness of debts	0	1,000
Interest expense	-98,686	-251,072
Total other income (expense)	334,340	-185,840
Net Income (Loss)	($352,865)	($715,546)
Loss per share
Basic and diluted	$0	($0.01)
Weighted average number of shares
Basic and diluted	94,507,750	117,248,274

CONSOLIDATED_STATEMENT_OF_STOC

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (USD $)	Common Shares	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 31, 2012	$117,248	$505,220	($1,089,363)	($466,895)
Beginning Balance, Shares at Dec. 31, 2012	117,248,000
Shares issued for convertible notes converted, Shares	100,000
Shares issued for convertible notes converted, Amount	100	80,979		81,079
Net loss			-715,546	-715,546
Ending Balance, amount at Dec. 31, 2013	117,348	586,199	-1,804,909	-1,101,362
Ending Balance, shares at Dec. 31, 2013	117,348,000
Shares issued for cash, Shares	815,963
Shares issued for cash, Amount	816	200,619		201,435
Shares issued from exercising of warrants, Shares	34,000
Shares issued from exercising of warrants, Amount	34	52,666		52,700
Shares issued for convertible notes converted, Shares	607,149
Shares issued for convertible notes converted, Amount	607	446,718		447,325
Shares purchase back by notes payable issuance, Shares	-67,666,619
Shares purchase back by notes payable issuance, Amount	-67,667	-12,000		-79,667
Shares purchase back by cash, Shares	-1,000,000
Shares purchase back by cash, Amount	-1,000			-1,000
Net loss			-352,865	-352,865
Ending Balance, amount at Dec. 31, 2014	$50,138	$1,274,202	($2,157,774)	($833,434)
Ending Balance, shares at Dec. 31, 2014	50,138,493

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities
Net loss	($352,865)	($715,546)
Adjustments to reconcile net income to net cash used in operating activities:
Gain on derivative valuation	-700,279	-64,232
Derivative expense	267,253	0
Gain on forgiveness of debts	0	-1,000
Amortization of discount on convertible debentures	75,901	182,197
Depreciation and amortization	6,695	4,200
Shares issued for services rendered	0	0
Change in current assets and current liabilities:
Inventory	66,031	54,546
Deposits	0
Other current assets	-3,536	1,905
Accounts payable and accrued expenses	144,302	150,521
Other current liabilities	2,713	0
Net cash used in operating activities	-493,785	-297,964
Cash flows from investing activities
Purchase of equipment	-18,335	-10,000
Payment in intangible assets	-15,000	0
Net cash used in investing activities	-33,335	-10,000
Cash flows from financing activities
Advances from (to) affiliate, net	152,939	131,968
Repayment of loan from affiliate	-119,672	-63,810
Proceeds from issuance of convertible debenture	0	124,000
Payment of common stock purchase back	-1,000	0
Proceeds from issuance of common stock	529,463	0
Net cash provided by financing activities	561,730	192,158
Net change in cash and cash equivalents	34,610	-115,806
Cash and cash equivalents, beginning balance	4,891	120,697
Cash and cash equivalents, ending balance	39,501	4,891
Supplemental disclosure of cash flow information
Income taxes paid	0	0
Interest paid	0	0
Non-cash transactions
Issued notes payable for common stock buyback	79,667	0
Issuance of common stock for convertible notes converted	447,325	0
Subscription receivable	$52,700	$0

1_Nature_of_Operations_and_Bas

1. Nature of Operations and Basis of Presentation	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
1. Nature of Operations and Basis of Presentation	1. Nature of Operations and Basis of Presentation
	Nature of Operations
	Technology Applications International Corporation (“Technology”) was incorporated on October 14, 2009 under the laws of Florida. Rejuvel Int’l, Inc. and NueEarth, Inc., Technology’s wholly owned subsidiaries and Technology, collectively, are referred to here-in as the “Company”. The Company is engaged in developing market entry technology products and services into early and mainstream technology products and services. Through our subsidiaries, we are focused on developing and manufacturing a line of technologically advanced skin care products and providing environmental management solutions that use electron particle accelerator technology.
	Principles of Consolidation
	The consolidated financial statements include the accounts of Technology Applications International Corporation and its wholly owned subsidiaries, Rejuvel Int’l, Inc. and NueEarth, Inc. All significant inter-company accounts and transactions have been eliminated in consolidation.
	Basis of Presentation and Going Concern Considerations
	The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) applicable to a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Realization values may be substantially different from carrying values as shown and these financial statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs. The Company’s ability to continue as a going concern is highly dependent upon management’s ability to increase near-term operating cash flows and obtain additional working capital through the issuance of debt and or equity.
	Management intends to finance operating costs over the next twelve months with existing cash on hand, from the issuance of common shares, and additional related party borrowings. The Company's future operations are dependent upon external funding and its ability to execute its business plan, realize sales and control expenses. Management believes that sufficient funding will be available from additional borrowings and private placements to meet its business objectives including anticipated cash needs for working capital, for a reasonable period of time. However, there can be no assurance that the Company will be able to obtain sufficient funds to continue the development of its business operation, or if obtained, upon terms favorable to the Company. If the Company is unable to obtain adequate capital, it could be forced to cease operations.
	Development Stage Risk
	Since its inception, the Company has been dependent upon the receipt of capital investment to fund its operating activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plans will be successfully executed. The Company’s ability to execute its business plans is dependent on its ability to obtain additional debt and equity financing and achieving a profitable level of operations. There can be no assurance that sufficient financing will be obtained or that we will achieve a profitable level of operations.
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and their reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Risks and Uncertainties
	The Company is subject to substantial risks from, among other things, intense competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements and limited operating history.
	Contingencies
	Certain conditions may exist as of the date the consolidated financial statements are issued which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company's management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company's legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.
	If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be provided for in the Company's consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.
	There were no contingencies which could be evaluated at December 31, 2014.
	Cash and Cash Equivalents
	Cash and cash equivalents consist of highly-liquid investments with a maturity of less than three months when purchased.
	Inventories
	Inventories are stated at the lower of cost or market value using the FIFO (first-in, first-out) method.
	The Company maintains a reserve for the inventory based on the estimated losses that result from inventory that becomes obsolete or for which the Company has excess inventory levels as of period end. In determining these estimates, the Company performs an analysis on current demand and usage for each inventory item over historical time periods. Based on that analysis, the Company reserves a percentage of the inventory amount within each time period based on historical demand and usage patterns of specific items in inventory.
	Machinery and Equipment
	Machinery and equipment are recorded at cost. Expenditures for maintenance and repairs are charged to earnings as incurred whereas additions, renewals and betterments are capitalized. When machinery and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of machinery and equipment is provided using the straight-line method over the assets estimated useful lives of approximately 5 to 7 years. Leasehold improvements, if any, are amortized on a straight-line basis over the term of the lease or the estimated useful lives, whichever is shorter.
	Intangible Assets
	Intangible consist of trademarks and licenses (Trademarks have a 20 year life and licenses have a 7 year life.) which are being amortized using the straight-line method over their estimated period of benefit. We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. All of our intangible assets are subject to amortization. No impairments of intangible assets have been identified during any of the periods presented.
	2015	2,252
	2016	2,252
	2017	2,252
	2018	2,252
	2019	2,252
	Thereafter	4,599
	Amortization expense for the years ended December 31, 2014 and 2013 was $1,082 and $109, respectively.
	Long-Lived Assets
	The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of definite-lived assets to be held and used is measured by comparison of the carrying amount of an asset to future undiscounted cash flow expected to be generated by the asset. If such assets are impaired, the impairment is recognized as the amount by which the carrying amount exceeds the estimated future cash flows. Assets to be sold are reported at the lower of the carrying amount or the fair value less costs to sell. Indefinite-lived assets are tested for impairment annually or when impairment is suspected by a comparison of the carrying amount of the asset to the net present value of future cash flows expected to be generated by the asset. There were no impaired assets at December 31, 2014.
	Revenue Recognition
	The Company's revenue recognition policies are in compliance with Staff Accounting Bulletin No. 104, "Revenue Recognition." Sales revenue which has been insignificant to December 31, 2014, is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue.
	Research and Development Costs
	Research and development costs, which relate primarily to the development, design and testing of products, are expensed as incurred. Such costs were approximately $6,563 and $8,319 for the years ended December 31, 2014 and 2013, respectively.
	Advertising and Marketing
	Advertising and marketing expenses are expensed as incurred. Expense recorded for the years ended December 31, 2014 and 2013 were approximately $102,886 and $86,442, respectively.
	Fair Value of Financial Instruments
	In accordance with FASB ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.
	In determining fair value, the Company uses various valuation approaches. In accordance with GAAP, a fair value hierarchy for inputs is used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the inputs market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels based on the inputs as follows:
	· Level 1 — Inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.
	· Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
	· Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
	As of December 31, 2014 and December 31, 2013, the derivative liabilities amounted to $48,851 and $349,940, respectively. In accordance with the accounting standards, the Company determined that the carrying value of these derivatives approximated the fair value using the level 2 inputs.
	Derivative Financial Instruments
	Derivative financial instruments, as defined in Financial Accounting Standards, consist of financial instruments or other contracts that contain a notional amount and one or more underlying components (e.g. interest rate, security price or other variable), require no initial net investment and permit net settlement. Derivative financial instruments may be free-standing or embedded in other financial instruments. Further, derivative financial instruments are initially, and subsequently, measured at fair value and recorded as liabilities or, in rare instances, assets. The Company generally does not use derivative financial instruments to hedge exposures to cash-flow or market or foreign-currency risks. However, the Company has entered into various types of financing arrangements to fund its business capital requirements, including convertible debt and other financial instruments indexed to the Company’s own stock. These contracts require careful evaluation to determine whether derivative features embedded in host contracts require bifurcation and fair value measurement or, in the case of freestanding derivatives (principally warrants) whether certain conditions for equity classification have been achieved. In instances where derivative financial instruments require liability classification, the Company is required to initially, and subsequently, measure such instruments at fair value. Accordingly, the Company adjusts the fair value of these derivative components at each reporting period through a charge to income until such time as the instruments acquire classification in stockholders’ equity. See Note 8 for additional information.
	As previously stated, derivative financial instruments are initially recorded at fair value and subsequently adjusted to fair value at the close of each reporting period. The Company estimates fair values of derivative financial instruments using various techniques (and combinations thereof) that are considered to be consistent with the objective measuring fair values. In selecting the appropriate technique, management considers, among other factors, the nature of the instrument, the market risks that it embodies and the expected means of settlement. For less complex derivative instruments, such as free-standing warrants, the Company uses the Black-Scholes-Merton option valuation technique because it embodies all of the requisite assumptions (including trading volatility, dividend yield, estimated terms and risk free rates) necessary to fair value these instruments. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are highly volatile and sensitive to changes in the trading market price of our common stock, which has a high-historical volatility. Since derivative financial instruments are initially, and subsequently, carried at fair values, our income (loss) will reflect the volatility in these estimate and assumption changes.
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income during the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses. No interest expense or penalties have been assessed as of, and for the years ended, December 31, 2014 and 2013.
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash accounts. The Company places its cash in what it believes to be credit-worthy financial institutions. Accounts at each financial institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At December 31, 2014 and 2013, the Company’s cash balances did not exceed federally insured limits.
	Earnings (Loss) Per Common Share
	The Company computes earnings per share in accordance with ASC 260, Earnings Per Share (“ASC 260”). Basic earnings (loss) per share are computed by dividing the net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted earnings per share adjusts basic earnings per share for the effects of stock options and other potentially dilutive financial instruments, only in the periods in which the effects are dilutive.
	For the years ended December 31, 2014 and 2013, there were warrants to purchase 189,963 shares and 100,000 shares, respectively, of common stock that were excluded from the diluted earnings per share computation because the impact of the assumed exercise of such warrants would have been anti-dilutive, based on the fact that their exercise price exceeded the market price of the common stock as of December 31, 2014 and 2013.
	Recent Accounting Pronouncements
	On June 10, 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-10 (ASU 2014-10), Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. ASU 2014-10 eliminates the requirement to present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclosure the risks and uncertainties related to their activities. ASU 2014-10 also eliminates an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The presentation and disclosure requirements in Topic 915 will no longer be required for interim and annual reporting periods beginning after December 15, 2014, and the revised consolidation standards will take effect in annual periods beginning after December 15, 2015. Early adoption is permitted. The Company adopted the provisions of ASU 2014-10 effective for its financial statements for the interim period ended September 30, 2014. The adoption of ASU 2014-10 did not have any effect on the Company’s financial statement presentation or disclosures.
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position or results of operations upon adoption.

2_Major_Customers

2. Major Customers	3 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
2. Major Customers	2. Major Customers
	Two customers accounted for approximately 74% and 70% of total sales for the years ended December 31, 2014 and 2013, respectively.

3_Commitments_and_Contingencie

3. Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
3. Commitments and Contingencies	3. Commitments and Contingencies
	The Company leases its corporate office space under a month to month lease.
	On September 10, 2014, the Company signed the office lease agreement. Commencement date is October 1, 2014 and lease term is 26 months. Monthly rental fee is $3,297 plus tax. The rent for October and November 2014 are free. Security deposit is $3,297 plus tax, which is $3,537. The first month for December 2014 and the last month rent are paid in 2014 amounting $7,056. Rental payment will be $42,333 in 2015 and $38,806 in 2016.
	Rent expense was approximately $16,034 and $4,194 for the years ended December 31, 2014 and 2013, respectively.
	During August 2012, the Company entered into a two-year commission agreement whereby it will pay a $35 commission for each product sold. The agreement will automatically renew in one-year increments unless cancelled in writing sixty-days prior to expiration.
	As of December 31, 2014 and through the date of these financial statements, the Company has no insurance policies in place. As of the date of these financial statements, the Company has not been advised of any liability or claims against it.

4_Inventories

4. Inventories	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
4. Inventories	4. Inventories
	Inventories, as of December 31, 2014 and 2013, consisted of the following:
		December 31,
			2014		2013
	Raw materials	$	-	$	-
	Work-in-process		-		-
	Finished goods		4,831		70,862
	Total Inventories, net	$	4,831	$	70,862
	No reserves for inventory have been deemed necessary at December 31, 2014 and 2013.

5_Machinery_and_Equipment

5. Machinery and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
5. Machinery and Equipment	5. Machinery and Equipment
	Machinery and equipment, as of December 31, 2014 and December 31, 2013, consisted of the following:
		Estimated Useful Lives	December	31-Dec-13
			31, 2014
	Computer Equipment	3 Years	$ 5,980	$ 4,162
	Machinery and equipment	5 Years	29,935	13,418
	Furniture and fixtures	7 Years	14,073	14,074
	Accumulated depreciation		-17,896	-12,283
			$ 32,092	$ 19,371
	Depreciation expense for the years ended December 31, 2014 and 2013 was $5,614 and $4,091, respectively.

6_Convertible_Debenture

6. Convertible Debenture	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
6. Convertible Debenture	6. Convertible Debenture
	During December 2011, the Company received $100,000 as a deposit for entering into a distribution agreement. On March 22, 2012, the Company converted the $100,000 deposit into a convertible debenture. The convertible debenture bears interest at a rate of five-percent (5%) per annum and was payable March 21, 2014. At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share. In addition to the common stock, the Holder received warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share. These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise. In December 2013, the Noteholder elected to convert $25,000 into 50,000 shares of the Company’s Common Stock at $0.50 per share. In February 2014, the Noteholder elected to convert $84,143 (including accrued interest of $9,143) into 168,285 shares of the Company’s Common Stock at $0.50 per share. The Company issued 218,285 warrants to purchase a 218,285 shares of common stock exercisable at $1.00 per share. As of December 31, 2014, 218,285 warrants are expired.
	On September 25, 2012, the Company issued a $100,000 convertible debenture. The convertible debenture bears interest at a rate of five-percent (5%) per annum and was payable September 20, 2013. At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share. In addition to the common stock, the Holder received warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share. These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise. This convertible debenture extended 360 days on September 21, 2013. In December 2013, the Noteholder elected to convert $25,000 into 50,000 shares of the Company’s Common Stock at $0.50 per share. In February 2014, the Noteholder elected to convert $88,273 (including accrued interest of $13,273) into 176,515 shares of the Company’s Common Stock at $0.50 per share. The Company issued 226,515 warrants to purchase a 226,515 shares of common stock exercisable at $1.00 per share. As of December 31, 2014, 226,515 warrants are expired.
	On April 3, May 23, May 31, June 10, July 29, August 14, and September 25, 2013 the Company issued $5,000, $10,000, $10,000, $25,000, $4,000, $50,000 and $20,000 convertible debentures, respectively. The convertible debentures bear interest at a rate of ten-percent (10%) per annum and is payable March 29, May 18, May 26, June 5, July 24, August 9, and September 20, 2014, respectively. At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share. In addition to the common stock, the Holder shall receive warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share. These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise. In February 2014, the Noteholder elected to convert $110,866 (including accrued interest of $6,866) into 220,785 shares of the Company’s Common Stock at $0.50 per share. The Company issued 220,785 warrants to purchase 220,785 shares of common stock exercisable at $1.00 per share. In April 2014, the Noteholder elected to convert $21,534 (including accrued interest of $1,534) into 41,534 shares of the Company’s Common Stock at $0.50 per share. The Company issued 41,534 warrants to purchase 41,534 shares of common stock exercisable at $1.00 per share. As of December 31, 2014, 262,319 warrants are expired.
	The Compound derivative comprises certain derivative features embedded in the host convertible debenture contracts including the conversion feature and warrants both of which contain anti-dilution protections. These instruments were combined into one compound derivative and bifurcated from the host instrument at fair value. The Company applied the Black-Scholes Merton valuation technique to fair value these derivatives because this technique embodies all of the assumptions necessary to fair value these compound derivative instruments. Since the derivative financial instruments are required to be recorded, both initially, and subsequently, at fair value, there were insufficient proceeds to allocate any amount to the convertible debentures and, accordingly, it has no carrying value on the date of inception. Additionally, proceeds were insufficient to record the fair values of the derivative financial instruments, resulting in initial interest expense of $267,253. It should be noted that the derivative instruments will be adjusted to fair value at each reporting date. As the Company does not have historical volatility data for its own stock, the expected volatility was based upon the Company’s peer group in the industry in which it does business. Fair values are highly influenced by the trading stock price and volatility of the peer group, changes in our credit risk and market interest rates. The company amortizes the discount on the convertible debentures resulting from the initial allocation over the term of the convertible debt instruments using the effective method. Amortization expense arising from this method for the years ended December 31, 2014 and 2013 amounted to $75,901 and $182,197 which have been included as a component of interest expense. For the year ended December 31, 2014, gain on derivative valuation was $700,279 (For the year ended December 31, 2013, gain on the derivative valuation was $64,232)

7_Common_Stock

7. Common Stock	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
7. Capital Stock	7. Common Stock
	In December 31, 2013, the Company issued 100,000 shares of its common stock at $0.50 for conversion of convertible debenture of $50,000. Also, the Company issued 100,000 warrants to purchase a 100,000 shares of common stock exercisable at $1.00 per share.
	In February 2014, the Company issued 565,615 shares of its common stock at $0.50 for conversion of convertible debentures of $254,000 and 29,282 of accrued interest.
	In March 2014, the Company issued 601,000 shares of its common stock at $0.50 through a private placement for total cash consideration of $300,500. Also, the Company issued 601,000 warrants to purchase to purchase 601,000 shares of common stock exercisable at $1.00 per share.
	On April 3, 2014, the Company entered stock subscription agreement of 5,000 shares at $1.00 per share with 5,000 warrants to purchase 5,000 shares of common stock with an exercise price of $2.00 per share. These warrants expired 180 days after stock issuance date.
	On April 8, 2014, the Company issued 41,534 shares of its common stock at $0.50 for conversion of a convertible debenture of $20,000 and $1,534 of accrued interest.
	On April 16, 2014, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 20,000 warrants to purchase 20,000 shares of common stock with an exercise price of $1.00 per share. These warrants expired 180 days after stock issuance date.
	On July 7, and July 31, 2014, the Company entered stock subscription agreements of 50,000 shares and 20,000 shares at $1.00 per share with 50,000 and 20,000 warrants to purchase 50,000 and 20,000 shares of common stock with an exercise price of $2.00 per share. These warrants expire 360 days after stock issuance date.
	On August 22, 2014, the Company entered stock subscription agreement of 99,963 shares at $1.00 per share with 99,963 warrants to purchase 99,963 shares of common stock with an exercise price of $2.00 per share. These warrants expire 360 days after stock issuance date.
	On August 28, 2014, the Company authorized the purchase of 64,666,619 shares of common stock from affiliate at $0.001 per share and signed a promissory note for a total of $64,667 to affect the purchase. The Company then cancelled the shares.
	On August 28, 2014, the Company authorized the purchase of 3,000,000 shares of common stock from shareholder at $0.005 per share and signed a promissory note for a total of $15,000 to affect the purchase. The Company then cancelled the shares.
	On September 9, 2014, a Warrant holder exercised 34,000 warrants to purchase 34,000 restricted common shares at a price of $1.00 per share.
	On August 28, 2014, the Company authorized the purchase of 1,000,000 shares of common stock from shareholder at $0.001 per share and paid by cash $1,000 to affect the purchase. The Company then cancelled the shares.
	On December 28, 2014, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 20,000 warrants to purchase 20,000 shares of common stock with an exercise price of $2.00 per share. These warrants expire 360 days after stock issuance date.
	Due to a ratchet provision, the warrants issued during 2014 were accounted for as a derivative and fair valued using the Black Scholes valuation model. The initial valuation was $561,281.
	Stock Purchase Warrants
	In conjunction with the Private Placement Memorandum dated February 13, 2013, the Company is offering up to 3,000,000 units. Each unit consists of 1 share of common stock priced at $1.00 and one Class A Warrant to purchase 1 share of common stock with an exercise price of $1.50 per share. These warrants expire on the earlier of (i) 180 days after the common stock commences quotation on the OTC Bulletin Board or (ii) one year after the date of issuance. No issuances have been sold from this offering as of December 31, 2014.
	In December 2013, Noteholders elected to convert $50,000 into 100,000 shares of the Company’s Common Stock at $0.50 per share. The Company issued 100,000 warrants to purchase 100,000 shares of common stock exercisable at $1.00 per share. The warrants were expired as of December 31, 2014.
	In February and April 2014, the Noteholder elected to convert $304,816 (including accrued interest of $30,816) into 607,149 shares of the Company’s Common Stock at $0.50 per share. The Company issued 607,149 warrants to purchase a 607,149 shares of common stock exercisable at $1.00 per share. The warrants were expired as of December 31, 2014.
	In March 2014, the Company issued 601,000 shares of its common stock at $0.50 through a private placement for total cash consideration of $300,500. Also, the Company issued 601,000 warrants to purchase 601,000 shares of common stock exercisable at $1.00 per share. 34,000 warrants were exercised in September 2014 and 567,000 warrants were expired as of December 31, 2014.
	On April 3, 2014, the Company entered stock subscription agreement of 5,000 shares at $1.00 per share with 5,000 warrants to purchase 5,000 shares of common stock with an exercise price of $2.00 per share. These warrants expire 180 days after stock issuance date. The warrants were expired as of December 31, 2014.
	On April 16, 2014, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 20,000 warrants to purchase 20,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 180 days after stock issuance date. The warrants were expired as of December 31, 2014.
	.
	On July 7, and July 31, 2014, the Company entered stock subscription agreements of 50,000 shares and 20,000 shares at $1.00 per share with 50,000 and 20,000 warrants to purchase 50,000 and 20,000 shares of common stock with an exercise price of $2.00 per share. These warrants expire 360 days after stock issuance date. As of December 31, 2014, 50,000 and 20,000 warrants are not exercised or expired.
	On August 22, 2014, the Company entered stock subscription agreement of 99,963 shares at $1.00 per share with 99,963 warrants to purchase 99,963 shares of common stock with an exercise price of $2.00 per share. These warrants expire 360 days after stock issuance date. As of December 31, 2014, 99,963 warrants are not exercised or expired.
	On December 28, 2014, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 20,000 warrants to purchase 20,000 shares of common stock with an exercise price of $2.00 per share. These warrants expire 360 days after stock issuance date. As of December 31, 2014, 20,000 warrants are not exercised or expired
	The following table summarizes all warrant activity for the years ended December 31, 2014 and 2013:
		Shares	Weighted-Average Exercise Price Per Share	Remaining	Intrinsic
				term	value
	Outstanding, December 31, 2013	100,000	1
	Exercisable at December 31, 2013	100,000	1
	Granted	1,423,112	1.16
	Exercised	-34,000	1
	Expired	-1,299,149	1.04	0.79 year	$0
	Exercisable at December 31, 2014	189,963	2	0.79 year	$0

8_Fair_Value_Measurements

8. Fair Value Measurements	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
8. Fair Value Measurements	8. Fair Value Measurements
	On a recurring basis, we measure certain financial assets and liabilities based upon the fair value hierarchy as described in the Company’s significant accounting policies in Note 1. The following table presents information about the Company’s liabilities measured at fair value as of December 31, 2014
		Level 1	Level 2	Level 3	Fair Value at December 31, 2014
	Liabilities
	Derivative liability	-	$48,851	-	$                  48,851
		Level 1	Level 2	Level 3	Fair Value at December 31, 2013
	Liabilities
	Derivative liability	-	$349,940	-	$                  349,940
	The fair value changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), relate solely to the derivative liability as follows:
	Balance at December 31, 2013	349,940
	Adjustment due to conversions	-141,294
	Adjustment due to exercise warrant	-18,700
	New warrant issued with stock	559,184
	Fair value adjustment	-700,279
	Balance at December 31, 2014	$ 48,851

9_Derivative_Financial_Instrum

9. Derivative Financial Instruments	12 Months Ended
	Dec. 31, 2014
Investments, All Other Investments [Abstract]
9. Derivative Financial Instruments	9. Derivative Financial Instruments
	The balance sheet caption derivative liability consists of derivative features embedded in convertible debentures including the conversion feature and warrants which have anti-dilution protections. These derivative financial instruments are indexed to an aggregate of 189,963 shares of the Company’s common stock as of December 31, 2014 and are carried at fair value. The balance at December 31, 2014 and 2013 was $48,851 and $349,940, respectively.
	The valuation of the derivative liability is determined using a Black-Scholes Merton Model because that model embodies all of the relevant assumptions that address the features underlying these instruments. Significant assumptions used in the Black-Scholes models at December 31, 2014 include the following:
	Risk-free interest rate	0.25%
	Estimated volatility	186%
	Dividend rate	None
	Estimated term in years	0.5-1.1

10_Income_Taxes

10. Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
10. Income Taxes	10. Income Taxes
	Deferred income taxes for 2014 and 2013 were provided for the temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities. The effects of temporary differences and carry-forwards at December 31, 2014 and 2013 are as follows:
	Deferred tax assets:		December 31,		December 31,
			2014		2013
	Net operating loss carry-over	$	733,642	$	613,669
	Derivative liability		-286,182		-48,097
	Common stock issued for services rendered		3,848		3,848
	Interest on derivative		242,693		151,827
	Valuation allowance		-773,283		-506,081
	Deferred tax assets per books	$	-	$	-
	The income tax provision differs from the amount of income tax determined by applying the estimated U.S. federal and state income tax rates of 34 percent to pretax income from continuing operations for the year ended December 31, 2014 and 2013 due to the following:
			December 31,		December 31,
			2014		2013
	Income tax expense at statutory rate	$	-119,974	$	-243,286
	Gain (loss) on derivative valuation		-238,095		-21,839
	Common stock issued for services rendered		-		-
	Interest on derivative		90,866		77,398
	Valuation allowance		267,203		187,727
	Income tax expense per books	$	-	$	-
	As of December 31, 2014, the Company had net operating loss carry forwards for income purposes of approximately $733,643 ($613,669 as of December 31, 2013) that may be offset against future taxable income. The net operating loss carry-forwards expire through the year 2034. Current tax laws limit the amount of loss available to be offset against future taxable income when a substantial change in ownership occurs or a change in the nature of the business. Therefore, the amount available to offset future taxable income may be limited.
	No tax benefit has been reported in the consolidated financial statements for the realization of loss carry-forwards, as the Company believes there is high probability that the carry-forwards will not be utilized in the foreseeable future.

11_Related_Parties

11. Related Parties	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
11. Related Parties	11. Related Parties
	An affiliate of the Company, the Company’s president, has been funding operations of the Company by making payments directly to third parties or advancing monies to the Company. These amounts bear no interest and are payable on demand. Amounts advanced to the Company during the years ended December 31, 2014 and 2013 were approximately $152,938 and $131,968, respectively. Payments of approximately $119,672 and $63,810 were made during the years ended December 31, 2014 and 2013, respectively, resulting in amounts due to the affiliate at December 31, 2014 and 2013 are approximately $270,747 and $237,480, respectively.
	During June 2012, the Company borrowed $125,000 from an affiliate. The loan bears interest at 10% per annum and is unsecured and payable upon demand. The Company has paid $0 toward the loan amount during 2014. The outstanding balance as of December 31, 2014 is $77,401 and accrued interest of $23,845.
	On August 28, 2014, the Company authorized the purchase of 64,666,619 shares of common stock from affiliate at $0.001 per share and signed an unsecured promissory note for a total of $64,667 to affect the purchase. The loan bears interest at 6% per annum and is unsecured and payable upon demand. The Company has paid $0 towards the loan amount during 2014. The outstanding balance as of December 31, 2014 is $64,667. During 2014, the Company accrued the interest $1,329.
	On August 28, 2014, the Company authorized the purchase of 3,000,000 shares of common stock from shareholder at $0.005 per share and signed a promissory note for a total of $15,000 to affect the purchase. The loan bears interest at 6% per annum and is unsecured and payable upon demand. The Company has paid $0 towards the loan amount during 2014. The outstanding balance as of December 31, 2014 is $15,000. During 2014, the Company accrued the interest $308.
	The Company periodically rents a recreational vehicle from an affiliate of the Company, an entity owned by the Company’s president, which is utilized for advertising and promotional events. The Company is charged $1,729 for each month of use and is payable in arrears. For the years ended December 31, 2014 and 2013, the Company recorded expense of approximately $3,237 and $1,052, respectively.

12_Significant_Agreement

12. Significant Agreement	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
12. Significant Agreement	12. Significant Agreement
	On September 30, 2013, the Company and its wholly-owned subsidiary Rejuvel Int’l, Inc., Florida corporations (the “Company”) entered into a partially exclusive Co-License Agreement (the “License Agreement”) by and amongst the National Aeronautics and Space Administration, an agency of the United States (“N.A.S.A.”) and the Administrators of the Tulane Educational Fund (“Tulane University”) for the use of U.S. Patent No. 6,730,498 B1, an invention entitled “Production of Functional Proteins: Balance of Shear Stress and Gravity,” which was issued on May 4, 2004 (the “Patent”). The company currently uses the Patent process to develop our anti-aging skin creams and shampoos. The License Agreement permits the Company to use the Patent as well as the name N.A.S.A., with its products, as per the terms of the License Agreement.
	On July 25, 2014, Technology Applications International Corporation and its wholly-owned subsidiary Rejuvel Int’l, Inc., Florida corporations (the “Company”) entered into an exclusive License Agreement (the “License Agreement”) by and between the National Aeronautics and Space Administration, an agency of the United States (“N.A.S.A.”) for the use of U.S. Patent No.’s 6,485,963 B1, an invention entitled “Growth Stimulation Of Biological Cells and Tissue By Electromagnetic Fields and Uses Thereof” which was filed on June 2, 2000, and U.S. Patent No. 6,673,597 B2, for an invention entitled “Growth Stimulation of Biological Cells and Tissue By Electromagnetic Fields and Uses Thereof, which was filed on February 28, 2001 (the “Patents”). We currently use the Patents process to develop our anti-aging skin creams and shampoos. The License Agreement permits the Company to use the Patents as well as the name N.A.S.A., with its products, as per the terms of the License Agreement.
	In consideration of the grant of the License Agreement, the Company will pay a 3% royalty to N.A.S.A. on the gross sales of any royalty-base products. The License agreement further requires the Company to remit to N.A.S.A. a non-refundable license fee in the amount of Fifteen Thousand Dollars ($15,000) upon the execution of the License Agreement and then another Fifteen Thousand Dollars ($15,000) is due six months after the license commencement date. The Company also agrees to pay N.A.S.A. a minimum royalty of Fifteen Thousand Dollars ($15,000), at the end of each accounting period (“Accounting Period”). The Accounting Period shall begin at the end of the second Accounting period of the License Agreement and each Accounting period thereafter.
	The License Agreement requires that the Company achieve a practical application of the Patent within eighteen (18) months from the commencement date of the License Agreement. In accordance with the appendix to the License Agreement; wherein it states that by August 2014, the Company shall have tested the product to meet federal, state and international regulations of its skin cream products, by October 2014, the Company shall have packaged and filled five products and by December 2014, the Company shall have Domestic and International distribution of five products. Once a practical application is achieved the term of the agreement shall be equal to the unexpired term of the last patent to be in effect of the patent(s) encompassed under the Patents. The Company further agrees that any products using the Patents process shall be substantially manufactured in the United States. As of the Date of this filing all milestones associated with the License Agreement have been completed on time and to the satisfaction of the License Agreement Parties.
	On October 4, 2013, the Company terminated its distribution agreement (“Distribution Agreement”) by and between the Company and Regenetech, Inc., a Texas corporation, pursuant to the termination clauses contained within the Distribution Agreement. Regenetech, Inc., was in a material breach of contract of the Distribution Agreement, because Regenetech, Inc., failed to upkeep its license requirements with N.A.S.A. and the Tulane University in order to maintain the license in good standing. Due to the material breach of contract by Regenetech, Inc., the termination of the Distribution Agreement does not contain any early termination penalties to the Company.

13_Subsequent_Events

13. Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
13. Subsequent Events	13. Subsequent Events
	On January 27, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of 1.00 per share. These warrants expire 360 days after stock issuance date.
	On February 2, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.
	On February 2, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.
	On February 3, 2015, the Company entered stock subscription agreement for 21,600 shares at $0.50 per share.
	On February 18, 2015, the Company entered stock subscription agreement of 50,000 shares at $0.50 per share with 50,000 warrants to purchase 50,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.
	On February 18, 2015, the Company entered a consulting agreement whereby the Company issued 15,000 shares for consulting services, on a month to month basis.
	On February 19, 2015, the Company entered a consulting agreement whereby the Company issued 25,000 shares for consulting services, on a month to month basis.
	On February 21, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.
	On February 21, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.
	On February 21, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.
	On February 23, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.
	On or about February 26, 2015, the Company entered into a distribution agreement (“Distribution Agreement”) with Yontem Cosmetics Dis Tic. Ltd. Sti (“Yontem”) a Turkish company; thereby, naming Turkey (the “Territory”) as an exclusive territory for Yontem. The terms of the Distribution Agreement, expects that Yontem will sell a minimum of 1,000 1.7oz units per month during the 1st year, 2,000 1.7oz units per month during the second year of operation and 3,000 units per month in the third year upon the establishment of the company by Yontem. The Distribution Agreement is for an initial period of three years and then the two parties will evaluate the progress of the Distribution Agreement. The Distribution Agreement can then be renewed for an additional five-five year periods. The Distribution Agreement also states that in order to maintain exclusivity on the Territory the quota numbers must be met, and that if they are not met then Yontem will lose exclusivity to the Territory.
	On March 6, 2015, the Company entered a service agreement whereby the Company issued 15,000 shares for marketing solution and strategy services, on a month to month basis.
	On March 10, 2015, the Company entered stock subscription agreement of 50,000 shares at $0.50 per share with 50,000 warrants to purchase 50,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.
	On March 10, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.
	On March 14, 2015, the Company entered an independent contractor agreement whereby the Company issued 100,000 shares for medical services, for a period of one year.
	On March 14, 2015, the Company entered an independent contractor agreement whereby the Company issued 10,000 shares for medical services, for a period of one year.
	Pursuant to Accounting Standards Codification 855-10, the Company has evaluated all events or transactions that have occurred from December 31, 2014 through the filing with the SEC.

x_Commitment

x. Commitment	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
9. Commitment	12. Significant Agreement
	On September 30, 2013, the Company and its wholly-owned subsidiary Rejuvel Int’l, Inc., Florida corporations (the “Company”) entered into a partially exclusive Co-License Agreement (the “License Agreement”) by and amongst the National Aeronautics and Space Administration, an agency of the United States (“N.A.S.A.”) and the Administrators of the Tulane Educational Fund (“Tulane University”) for the use of U.S. Patent No. 6,730,498 B1, an invention entitled “Production of Functional Proteins: Balance of Shear Stress and Gravity,” which was issued on May 4, 2004 (the “Patent”). The company currently uses the Patent process to develop our anti-aging skin creams and shampoos. The License Agreement permits the Company to use the Patent as well as the name N.A.S.A., with its products, as per the terms of the License Agreement.
	On July 25, 2014, Technology Applications International Corporation and its wholly-owned subsidiary Rejuvel Int’l, Inc., Florida corporations (the “Company”) entered into an exclusive License Agreement (the “License Agreement”) by and between the National Aeronautics and Space Administration, an agency of the United States (“N.A.S.A.”) for the use of U.S. Patent No.’s 6,485,963 B1, an invention entitled “Growth Stimulation Of Biological Cells and Tissue By Electromagnetic Fields and Uses Thereof” which was filed on June 2, 2000, and U.S. Patent No. 6,673,597 B2, for an invention entitled “Growth Stimulation of Biological Cells and Tissue By Electromagnetic Fields and Uses Thereof, which was filed on February 28, 2001 (the “Patents”). We currently use the Patents process to develop our anti-aging skin creams and shampoos. The License Agreement permits the Company to use the Patents as well as the name N.A.S.A., with its products, as per the terms of the License Agreement.
	In consideration of the grant of the License Agreement, the Company will pay a 3% royalty to N.A.S.A. on the gross sales of any royalty-base products. The License agreement further requires the Company to remit to N.A.S.A. a non-refundable license fee in the amount of Fifteen Thousand Dollars ($15,000) upon the execution of the License Agreement and then another Fifteen Thousand Dollars ($15,000) is due six months after the license commencement date. The Company also agrees to pay N.A.S.A. a minimum royalty of Fifteen Thousand Dollars ($15,000), at the end of each accounting period (“Accounting Period”). The Accounting Period shall begin at the end of the second Accounting period of the License Agreement and each Accounting period thereafter.
	The License Agreement requires that the Company achieve a practical application of the Patent within eighteen (18) months from the commencement date of the License Agreement. In accordance with the appendix to the License Agreement; wherein it states that by August 2014, the Company shall have tested the product to meet federal, state and international regulations of its skin cream products, by October 2014, the Company shall have packaged and filled five products and by December 2014, the Company shall have Domestic and International distribution of five products. Once a practical application is achieved the term of the agreement shall be equal to the unexpired term of the last patent to be in effect of the patent(s) encompassed under the Patents. The Company further agrees that any products using the Patents process shall be substantially manufactured in the United States. As of the Date of this filing all milestones associated with the License Agreement have been completed on time and to the satisfaction of the License Agreement Parties.
	On October 4, 2013, the Company terminated its distribution agreement (“Distribution Agreement”) by and between the Company and Regenetech, Inc., a Texas corporation, pursuant to the termination clauses contained within the Distribution Agreement. Regenetech, Inc., was in a material breach of contract of the Distribution Agreement, because Regenetech, Inc., failed to upkeep its license requirements with N.A.S.A. and the Tulane University in order to maintain the license in good standing. Due to the material breach of contract by Regenetech, Inc., the termination of the Distribution Agreement does not contain any early termination penalties to the Company.

1_Nature_of_Operations_and_Bas1

1. Nature of Operations and Basis of Presentation (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations
	Technology Applications International Corporation (“Technology”) was incorporated on October 14, 2009 under the laws of Florida. Rejuvel Int’l, Inc. and NueEarth, Inc., Technology’s wholly owned subsidiaries and Technology, collectively, are referred to here-in as the “Company”. The Company is engaged in developing market entry technology products and services into early and mainstream technology products and services. Through our subsidiaries, we are focused on developing and manufacturing a line of technologically advanced skin care products and providing environmental management solutions that use electron particle accelerator technology.
Principles of Consolidation	Principles of Consolidation
	The consolidated financial statements include the accounts of Technology Applications International Corporation and its wholly owned subsidiaries, Rejuvel Int’l, Inc. and NueEarth, Inc. All significant inter-company accounts and transactions have been eliminated in consolidation.
Basis of Presentation and Going Concern Considerations	Basis of Presentation and Going Concern Considerations
	The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) applicable to a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Realization values may be substantially different from carrying values as shown and these financial statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs. The Company’s ability to continue as a going concern is highly dependent upon management’s ability to increase near-term operating cash flows and obtain additional working capital through the issuance of debt and or equity.
	Management intends to finance operating costs over the next twelve months with existing cash on hand, from the issuance of common shares, and additional related party borrowings. The Company's future operations are dependent upon external funding and its ability to execute its business plan, realize sales and control expenses. Management believes that sufficient funding will be available from additional borrowings and private placements to meet its business objectives including anticipated cash needs for working capital, for a reasonable period of time. However, there can be no assurance that the Company will be able to obtain sufficient funds to continue the development of its business operation, or if obtained, upon terms favorable to the Company. If the Company is unable to obtain adequate capital, it could be forced to cease operations.
Development Stage Risk	Development Stage Risk
	Since its inception, the Company has been dependent upon the receipt of capital investment to fund its operating activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plans will be successfully executed. The Company’s ability to execute its business plans is dependent on its ability to obtain additional debt and equity financing and achieving a profitable level of operations. There can be no assurance that sufficient financing will be obtained or that we will achieve a profitable level of operations.
Use of Estimates	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and their reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Risks and Uncertainties	Risks and Uncertainties
	The Company is subject to substantial risks from, among other things, intense competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements and limited operating history.
Contingencies	Contingencies
	Certain conditions may exist as of the date the consolidated financial statements are issued which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company's management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company's legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.
	If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be provided for in the Company's consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.
	There were no contingencies which could be evaluated at December 31, 2014.
Cash and Cash Equivalents	Cash and Cash Equivalents
	Cash and cash equivalents consist of highly-liquid investments with a maturity of less than three months when purchased.
Inventories	Inventories
	Inventories are stated at the lower of cost or market value using the FIFO (first-in, first-out) method.
	The Company maintains a reserve for the inventory based on the estimated losses that result from inventory that becomes obsolete or for which the Company has excess inventory levels as of period end. In determining these estimates, the Company performs an analysis on current demand and usage for each inventory item over historical time periods. Based on that analysis, the Company reserves a percentage of the inventory amount within each time period based on historical demand and usage patterns of specific items in inventory.
Machinery and Equipment	Machinery and Equipment
	Machinery and equipment are recorded at cost. Expenditures for maintenance and repairs are charged to earnings as incurred whereas additions, renewals and betterments are capitalized. When machinery and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of machinery and equipment is provided using the straight-line method over the assets estimated useful lives of approximately 5 to 7 years. Leasehold improvements, if any, are amortized on a straight-line basis over the term of the lease or the estimated useful lives, whichever is shorter.
Intangible Assets	Intangible Assets
	Intangible consist of trademarks and licenses (Trademarks have a 20 year life and licenses have a 7 year life.) which are being amortized using the straight-line method over their estimated period of benefit. We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. All of our intangible assets are subject to amortization. No impairments of intangible assets have been identified during any of the periods presented.
	2015	2,252
	2016	2,252
	2017	2,252
	2018	2,252
	2019	2,252
	Thereafter	4,599
	Amortization expense for the years ended December 31, 2014 and 2013 was $1,082 and $109, respectively.
Long-Lived Assets	Long-Lived Assets
	The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of definite-lived assets to be held and used is measured by comparison of the carrying amount of an asset to future undiscounted cash flow expected to be generated by the asset. If such assets are impaired, the impairment is recognized as the amount by which the carrying amount exceeds the estimated future cash flows. Assets to be sold are reported at the lower of the carrying amount or the fair value less costs to sell. Indefinite-lived assets are tested for impairment annually or when impairment is suspected by a comparison of the carrying amount of the asset to the net present value of future cash flows expected to be generated by the asset. There were no impaired assets at December 31, 2014.
Revenue Recognition	Revenue Recognition
	The Company's revenue recognition policies are in compliance with Staff Accounting Bulletin No. 104, "Revenue Recognition." Sales revenue which has been insignificant to December 31, 2014, is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue.
Research and Development Costs	Research and Development Costs
	Research and development costs, which relate primarily to the development, design and testing of products, are expensed as incurred. Such costs were approximately $6,563 and $8,319 for the years ended December 31, 2014 and 2013, respectively.
Advertising and Marketing	Advertising and Marketing
	Advertising and marketing expenses are expensed as incurred. Expense recorded for the years ended December 31, 2014 and 2013 were approximately $102,886 and $86,442, respectively.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	In accordance with FASB ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.
	In determining fair value, the Company uses various valuation approaches. In accordance with GAAP, a fair value hierarchy for inputs is used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the inputs market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels based on the inputs as follows:
	· Level 1 — Inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.
	· Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
	· Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
	As of December 31, 2014 and December 31, 2013, the derivative liabilities amounted to $48,851 and $349,940, respectively. In accordance with the accounting standards, the Company determined that the carrying value of these derivatives approximated the fair value using the level 2 inputs.
Derivative Financial Instruments	Derivative Financial Instruments
	Derivative financial instruments, as defined in Financial Accounting Standards, consist of financial instruments or other contracts that contain a notional amount and one or more underlying components (e.g. interest rate, security price or other variable), require no initial net investment and permit net settlement. Derivative financial instruments may be free-standing or embedded in other financial instruments. Further, derivative financial instruments are initially, and subsequently, measured at fair value and recorded as liabilities or, in rare instances, assets. The Company generally does not use derivative financial instruments to hedge exposures to cash-flow or market or foreign-currency risks. However, the Company has entered into various types of financing arrangements to fund its business capital requirements, including convertible debt and other financial instruments indexed to the Company’s own stock. These contracts require careful evaluation to determine whether derivative features embedded in host contracts require bifurcation and fair value measurement or, in the case of freestanding derivatives (principally warrants) whether certain conditions for equity classification have been achieved. In instances where derivative financial instruments require liability classification, the Company is required to initially, and subsequently, measure such instruments at fair value. Accordingly, the Company adjusts the fair value of these derivative components at each reporting period through a charge to income until such time as the instruments acquire classification in stockholders’ equity. See Note 8 for additional information.
	As previously stated, derivative financial instruments are initially recorded at fair value and subsequently adjusted to fair value at the close of each reporting period. The Company estimates fair values of derivative financial instruments using various techniques (and combinations thereof) that are considered to be consistent with the objective measuring fair values. In selecting the appropriate technique, management considers, among other factors, the nature of the instrument, the market risks that it embodies and the expected means of settlement. For less complex derivative instruments, such as free-standing warrants, the Company uses the Black-Scholes-Merton option valuation technique because it embodies all of the requisite assumptions (including trading volatility, dividend yield, estimated terms and risk free rates) necessary to fair value these instruments. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are highly volatile and sensitive to changes in the trading market price of our common stock, which has a high-historical volatility. Since derivative financial instruments are initially, and subsequently, carried at fair values, our income (loss) will reflect the volatility in these estimate and assumption changes.
Income Taxes	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income during the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses. No interest expense or penalties have been assessed as of, and for the years ended, December 31, 2014 and 2013.
Concentration of Credit Risk	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash accounts. The Company places its cash in what it believes to be credit-worthy financial institutions. Accounts at each financial institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At December 31, 2014 and 2013, the Company’s cash balances did not exceed federally insured limits.
Earnings (Loss) Per Common Share	Earnings (Loss) Per Common Share
	The Company computes earnings per share in accordance with ASC 260, Earnings Per Share (“ASC 260”). Basic earnings (loss) per share are computed by dividing the net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted earnings per share adjusts basic earnings per share for the effects of stock options and other potentially dilutive financial instruments, only in the periods in which the effects are dilutive.
	For the years ended December 31, 2014 and 2013, there were warrants to purchase 189,963 shares and 100,000 shares, respectively, of common stock that were excluded from the diluted earnings per share computation because the impact of the assumed exercise of such warrants would have been anti-dilutive, based on the fact that their exercise price exceeded the market price of the common stock as of December 31, 2014 and 2013.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	On June 10, 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-10 (ASU 2014-10), Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. ASU 2014-10 eliminates the requirement to present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclosure the risks and uncertainties related to their activities. ASU 2014-10 also eliminates an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The presentation and disclosure requirements in Topic 915 will no longer be required for interim and annual reporting periods beginning after December 15, 2014, and the revised consolidation standards will take effect in annual periods beginning after December 15, 2015. Early adoption is permitted. The Company adopted the provisions of ASU 2014-10 effective for its financial statements for the interim period ended September 30, 2014. The adoption of ASU 2014-10 did not have any effect on the Company’s financial statement presentation or disclosures.
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position or results of operations upon adoption.

4_Inventories_Tables

4. Inventories (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventories		December 31,
			2014		2013
	Raw materials	$	-	$	-
	Work-in-process		-		-
	Finished goods		4,831		70,862
	Total Inventories, net	$	4,831	$	70,862

5_Machinery_and_Equipment_Tabl

5. Machinery and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Machinery and equipment		Estimated Useful Lives	December	31-Dec-13
			31, 2014
	Computer Equipment	3 Years	$ 5,980	$ 4,162
	Machinery and equipment	5 Years	29,935	13,418
	Furniture and fixtures	7 Years	14,073	14,074
	Accumulated depreciation		-17,896	-12,283
			$ 32,092	$ 19,371

7_Common_Stock_Tables

7. Common Stock (Tables)	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Warrant Activity		Shares	Weighted-Average Exercise Price Per Share	Remaining	Intrinsic
				term	value
	Outstanding, December 31, 2013	100,000	1
	Exercisable at December 31, 2013	100,000	1
	Granted	1,423,112	1.16
	Exercised	-34,000	1
	Expired	-1,299,149	1.04	0.79 year	$0
	Exercisable at December 31, 2014	189,963	2	0.79 year	$0

8_Fair_Value_Measurements_Tabl

8. Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Derivative Liabilities		Level 1	Level 2	Level 3	Fair Value at December 31, 2014
	Liabilities
	Derivative liability	-	$48,851	-	$                  48,851
		Level 1	Level 2	Level 3	Fair Value at December 31, 2013
	Liabilities
	Derivative liability	-	$349,940	-	$                  349,940
Derivative Liability Fair Value Adjustment	Balance at December 31, 2013	349,940
	Adjustment due to conversions	-141,294
	Adjustment due to exercise warrant	-18,700
	New warrant issued with stock	559,184
	Fair value adjustment	-700,279
	Balance at December 31, 2014	$ 48,851

9_Derivative_Financial_Instrum1

9. Derivative Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2014
Investments, All Other Investments [Abstract]
Valuation of derivative liability	Risk-free interest rate	0.25%
	Estimated volatility	186%
	Dividend rate	None
	Estimated term in years	0.5-1.1

10_Income_Taxes_Tables

10. Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Deferred Tax Assets	Deferred tax assets:		December 31,		December 31,
			2014		2013
	Net operating loss carry-over	$	733,642	$	613,669
	Derivative liability		-286,182		-48,097
	Common stock issued for services rendered		3,848		3,848
	Interest on derivative		242,693		151,827
	Valuation allowance		-773,283		-506,081
	Deferred tax assets per books	$	-	$	-
Income Tax Provision			December 31,		December 31,
			2014		2013
	Income tax expense at statutory rate	$	-119,974	$	-243,286
	Gain (loss) on derivative valuation		-238,095		-21,839
	Common stock issued for services rendered		-		-
	Interest on derivative		90,866		77,398
	Valuation allowance		267,203		187,727
	Income tax expense per books	$	-	$	-

1_Nature_of_Operations_and_Bas2

1. Nature of Operations and Basis of Presentation (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2020	Jan. 01, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Notes to Financial Statements
Amortization expense related to trademarks	$1,082	$109
Estimated future amortization expense related to trademarks	2,252		2,252	4,599	2,252	2,252	2,252	2,252	2,252
Research and development costs	6,653	8,319
Advertising and marketing costs	102,886	86,442
Derivative liabilities	48,851	349,940
FDIC insured value		250,000
Oustanding warrants	189,963	100,000
Impaired assets	0
Interest expense	$0	$0

2_Major_Customers_Details_Narr

2. Major Customers (Details Narrative)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Notes to Financial Statements
Major Customers	2	2
Total sales from major customers	74.00%	70.00%

3_Commitments_and_Contingencie1

3. Commitments and Contingencies (Details Narrative) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended
	Sep. 11, 2014	Aug. 31, 2012	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Rental Lease commitment	26 months				26 months
Monthly office rental fee					$3,297
Security Deposit on office rental					3,537
Rent expense					16,034	4,194
Future rent expense			38,806	42,333
Commission agreement amount per product sold		$35
Period of commission agreement		2 years
Automatic commission agreement renewal increments		1 year
Advance cancellation notice required on commission agreement expiration		60 days

4_Inventories_Details

4. Inventories (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Inventory Disclosure [Abstract]
Raw materials	$0	$0
Work-in-process	0	0
Finished goods	4,831	70,862
Total Inventories	$4,831	$70,862

5_Machinery_and_Equipment_Deta

5. Machinery and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014
Computer Equipment	4,162	$5,980
Machinery and equipment	13,418	29,935
Furniture and fixtures	14,073	14,073
Accumulated depreciation	-12,282	-17,896
Machinery and equipment, net	19,371	$32,092
Computer Equipment
Estimated useful lives, min	3 years
Machinery and Equipment
Estimated useful lives, min	5 years
Estimated useful lives, max	7 years
Furniture and Fixtures
Estimated useful lives, min	7 years

5_Machinery_and_Equipment_Deta1

5. Machinery and Equipment (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Depreciation expense	$5,614	$4,091

6_Convertible_Debenture_Detail

6. Convertible Debenture (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Notes to Financial Statements
Compound derivative	$267,253	$0
Interest expense	$0	$0

6_Convertible_Debenture_Detail1

6. Convertible Debenture (Details Narrative) (USD $)	1 Months Ended				12 Months Ended
	Apr. 30, 2014	Feb. 28, 2014	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2014	Dec. 31, 2013	Mar. 10, 2015	Feb. 23, 2015	Feb. 21, 2015	Feb. 18, 2015	Feb. 02, 2015	Jan. 27, 2015	Aug. 28, 2014	Apr. 16, 2014	Apr. 03, 2014	Sep. 25, 2013	Aug. 14, 2013	Jul. 29, 2013	Jun. 10, 2013	31-May-13	23-May-13	Apr. 03, 2013	Sep. 25, 2012	Mar. 22, 2012
Notes to Financial Statements
Deposit on distribution agreeement				$100,000
Deposit converted into convertible debenture																								100,000
Convertible debenture issued																20,000	50,000	4,000	25,000	10,000	10,000	5,000	100,000
Interest rate of convertible debenture, per annum																10.00%	10.00%	10.00%	10.00%	10.00%	10.00%	0.00%	5.00%	5.00%
Maturity date of convertible debenture						1 year
Debt conversion to common stock rate																$0.50	$0.50	$0.50	$0.50	$0.50	$0.50	$0.50	$0.50	$0.50
Number of warrants offered per share issued from converted debt																1	1	1	1	1	1	1	1	1
Warrants exercisable for common stock, price per share							$1	$1	$1	$1	$1	$1	$1	$1	$2	$1	$1	$1	$1	$1	$1	$1	$1	$1
Expiration of warrants, years						1 year
Expiration of warrants, days after common stock is quoted on OTCBB						180 days
Initial Interest expense					267,253
Amortization expense					75,901	182,197
Gain (loss) on derivative valuation					700,279	64,232
Amount of debt converted from debentures					254,000
Shares of common stock issued from conversion of debentures					485,000
Amount of convertible debentures still outstanding					19,999
Debt discount on convertible debt					9,611
Net convertible debt					10,388
Amount of debt converted from 2013 debentures	20,767	110,866
Shares of common stock issued from conversion of 2013 debentures	41,543	220,785
Price per share of common stock converted from 2013 debentures		$0.50
Warrants issued for 2013 debentures	41,534	220,785
Exercise price of warrants issued for 2013 debentures	$1	$1
Expiration period of warrants issued for 2013 debentures		21-Sep-14
Warrants outstanding of the 2013 debenture warrants					0
Amount of 2013 convertible debentures still outstanding					21,025
Amount of debt converted from December 2011 debenture		84,143	25,000
Shares of common stock issued from conversion of December 2011 debenture		168,285	50,000
Price per share of common stock converted from December 2011 debenture			$0.50
Amount of debt converted from September 2012 debenture		88,273	25,000
Shares of common stock issued from conversion of September 2012 debenture		176,515	50,000
Price per share of common stock converted from September 2012 debenture		$0.50	$0.50
Warrants issued for December 2011 debenture		218,285
Exercise price of warrants issued for December 2011 debenture		$1
Expiration date of warrants issued for December 2011 debenture		21-Sep-14
Warrants outstanding of the December 2011 debenture warrants					0
Warrants issued for September 2012 debenture		226,515
Exercise price of warrants issued for September 2012 debenture		$1
Expiration date of warrants issued for September 2012 debenture		21-Sep-14
Warrants outstanding of the September 2012 debenture warrants					0
Unsecured promissory note due RAJ Ventures													$15,000
Interest rate of promissory note due RAJ Ventures													6.00%

7_Common_Stock_Details

7. Common Stock (Details) (USD $)	1 Months Ended	24 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013
Number of Warrant Shares, duration	601,000	1,030,000
Exercisable
Number of Warrant Shares, instant			189,963	100,000
Weighted Average Exercise Price, instant			$1.60	$1
Intrinsic Value, instant			$0
Outstanding
Number of Warrant Shares, instant				100,000
Weighted Average Exercise Price, instant				$1
Expired
Number of Warrant Shares, duration			-1,299,149
Weighted Average Exercise Price, duration			$1.04
Remaining term, duration			9 months
Intrinsic Value, duration			$0
Exercised
Number of Warrant Shares, duration			-34,000
Granted
Number of Warrant Shares, duration			1,403,112
Weighted Average Exercise Price, duration			$1.12

7_Common_Stock_Details_Narrati

7. Common Stock (Details Narrative) (USD $)	1 Months Ended				3 Months Ended		12 Months Ended		24 Months Ended
	Apr. 30, 2014	Mar. 31, 2014	Feb. 28, 2014	Dec. 31, 2013	Sep. 30, 2014	Apr. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 14, 2015	Mar. 10, 2015	Mar. 06, 2015	Feb. 23, 2015	Feb. 21, 2015	Feb. 19, 2015	Feb. 18, 2015	Feb. 03, 2015	Feb. 02, 2015	Jan. 27, 2015	Dec. 28, 2014	Aug. 28, 2014	Aug. 22, 2014	Jul. 31, 2014	Jul. 07, 2014	Apr. 16, 2014	Apr. 03, 2014	Sep. 25, 2013	Aug. 14, 2013	Jul. 29, 2013	Jun. 10, 2013	31-May-13	23-May-13	Apr. 03, 2013	Feb. 13, 2013	Sep. 25, 2012	Mar. 22, 2012
				Units				Units																										Units
Notes to Financial Statements
Common stock issued for cash, shares											52,000		10,000	14,000		50,000	216,000	12,000	10,000	20,000		99,963	20,000	50,000	20,000	5,000
Common stock issued for cash, value																						$99,963	$20,000	$50,000	$10,000	$5,000
Common stock issued for cash, shares, duration		601,000
Common stock issued for cash, value, duration		300,500					201,435
Common stock issued for services, shares										110,000		15,000			25,000	15,000
Private placement units offered																																		3,000,000
Shares per unit																																		1
Common stock price per share											$0.50		$0.50	$0.50		$0.50	$0.50		$0.50	$0.50		$1	$1	$1	$0.50	$1								$1
Warrants per unit																																		1
Class A Warrants, shares per warrant																																		1
Exercise price per share in warrant																				$2														$1.50
Expiration of warrants, years								1 year
Expiration of warrants, days after common stock is quoted on OTCBB								180 days
Number of untis sold in February 13, 2013 private offering				0				0
Number of warrant shares issued, shares		601,000							1,030,000
Common stock issued for debt, shares, duration	41,534		565,615	100,000		607,119
Common stock issued for debt, amount, duration	20,000		254,000	50,000		304,049
Common stock issued for debt, price per share	$0.50		$0.50	$0.50		$0.50
Common stock issued for accrued interest on debt, amount, duration	1,534		29,282
Common stock issued for cash, price per share		$0.50
Warrants issued for debenture conversion		485,000		100,000		607,119
Exercise price of warrants issued for debenture conversion		$1		$1		$1
Subscription receivable		66,500
Exercise price of warrants issued for stock purchase, duration		$1			$2
Warrant expiration period	180 days				1 year		1 year
Valuation of warrants issued					525,623		561,281
Warrants included in stock issuance											52,000		10,000	14,000		50,000		12,000	10,000	20,000		99,963	20,000	50,000	20,000	5,000
Shares underlying warrants in stock issuance											52,000		10,000	14,000		50,000		12,000	10,000	20,000		99,963	20,000	50,000	20,000	5,000
Exercise price of warrants in stock issuance											$1		$1	$1		$1		$1	$1		$1				$1	$2	$1	$1	$1	$1	$1	$1	$1		$1	$1
Warrants issued for March/April 2014 debenture			226,515
Exercise price of warrants issued for March/April 2014 debenture			$1
Amount of debt converted from debentures							$254,000
Shares of common stock issued from conversion of debentures							485,000
Shares repurchased from shareholders and returned to treasury					68,666,619
Warrants exercised																					34,000
Exercise price of warrants exercised											$1		$1	$1		$1		$1	$1		$1				$1	$2	$1	$1	$1	$1	$1	$1	$1		$1	$1
Shares issued from exercise of warrants																					34,000

8_License_Agreement_Derivative

8. License Agreement - Derivative Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Derivative liability	$48,851	$349,940
Level 1
Derivative liability	0	0
Level 2
Derivative liability	48,851	349,940
Level 3
Derivative liability	0	0
Fair Value
Derivative liability	$48,851	$349,940

8_License_Agreement_Derivative1

8. License Agreement - Derivative Liability Fair Value Adjustment (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Notes to Financial Statements
Derivative liability	$48,851	$349,940
Fair value adjustment	700,279	64,232
Adjustment due to conversion	-141,294
Adjustment due to exercise warrant	-18,700
New warrant issued with stock	$559,184

8_License_Agreement_Details_Na

8. License Agreement (Details Narrative) (USD $)	3 Months Ended
	Sep. 30, 2014	Jul. 25, 2014
		Products
		Patents
Notes to Financial Statements
Royalty percent paid to NASA for use of two patent in exclusive License Agreement		3.00%
Number of patents included in exclusive License Agreement with NASA		2
Non-refundable license fee paid to NASA upon execution of License Agreement		$15,000
Second License Agreement fee due to NASA		15,000
Due date of second license fee due to NASA	6 months
Minimum annual royalty due to NASA for License Agreement		$15,000
Required time period to reach practical application of patents with License Agreement	18 months
Required number of products required to be filled, packaged, and have distribution by December 2014		5

9_Derivative_Financial_Instrum2

9. Derivative Financial Instruments - Black-Sholes Assumptions (Details)	12 Months Ended
	Dec. 31, 2014
Investments, All Other Investments [Abstract]
Risk free interest rate	0.25%
Estimated volatility	186.00%
Dividend rate	0.00%
Estimated term in years, max	6 months
Estimated term in years, min	1 year 1 month

9_Derivative_Financial_Instrum3

9. Derivative Financial Instruments (Details Narrative)	Dec. 31, 2014
Notes to Financial Statements
Derivative financial instruments are indexed to an aggregate amount of shares	189,963

10_Income_Tax_Provision_Detail

10. Income Tax Provision (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Income tax expense at statutory rate	$119,974	($243,286)
Change in derivative liability	-238,095	21,839
Common stock issued for services rendered	0	0
Interest on derivative	90,866	77,398
Valuation allowance	267,203	187,726
Income tax expense per books	$0	$0

10_Income_Taxes_Details_Narrat

10. Income Taxes (Details Narrative)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Federal and state income tax rate	34.00%	34.00%
NOL carry-forwards expire through year	2033	2033

11_Related_Parties_Details_Nar

11. Related Parties (Details Narrative) (USD $)	1 Months Ended	12 Months Ended
	Jun. 30, 2012	Dec. 31, 2014	Dec. 31, 2013
Related Party Transactions [Abstract]
Affiliate advances		$152,938	$131,968
Payments made on affiliate advances		119,672	63,810
Due to affiliates		270,747	237,480
Loan from affiliate	125,000
Interest rate on loan from affiliate	10.00%
Repayments on loan from affiliate	0		11,479
Oustanding balance on loan from affiliate		77,401
Periodic monthly rental fee for President's recreational vehicle			1,052
Monthly rent cost for President's recreational vehicle		1,729	1,729
Recorded expense		3,237	1,052
Accrued interest	$23,845		$8,225

12_Significant_Agreement_Detai

12. Significant Agreement (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014
Co-License Agreement on Patent
Royalty percent paid to NASA per the patent license	3.00%
Minimum royalty due to NASA per calendar year accounting period	$15,000
Total royalty due per calendar year accounting period	$15,000
Months to achieve practical application of patent required by license	18 months

13_Subsequent_Events_Details_N

13. Subsequent Events (Details Narrative) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended
	Feb. 26, 2015	Feb. 28, 2014	Dec. 31, 2014	Mar. 14, 2015	Mar. 10, 2015	Mar. 06, 2015	Feb. 23, 2015	Feb. 21, 2015	Feb. 19, 2015	Feb. 18, 2015	Feb. 03, 2015	Feb. 02, 2015	Jan. 27, 2015	Dec. 28, 2014	Aug. 28, 2014	Aug. 22, 2014	Jul. 31, 2014	Jul. 07, 2014	Apr. 16, 2014	Apr. 03, 2014	Sep. 25, 2013	Aug. 14, 2013	Jul. 29, 2013	Jun. 10, 2013	31-May-13	23-May-13	Apr. 03, 2013	Feb. 13, 2013	Sep. 25, 2012	Mar. 22, 2012
Subsequent Events [Abstract]
Common stock issued for cash, shares					52,000		10,000	14,000		50,000	216,000	12,000	10,000	20,000		99,963	20,000	50,000	20,000	5,000
Common stock issued for cash, value																$99,963	$20,000	$50,000	$10,000	$5,000
Common stock issued for cash, price per share					$0.50		$0.50	$0.50		$0.50	$0.50		$0.50	$0.50		$1	$1	$1	$0.50	$1								$1
Warrants included in stock issuance					52,000		10,000	14,000		50,000		12,000	10,000	20,000		99,963	20,000	50,000	20,000	5,000
Shares underlying warrants in stock issuance					52,000		10,000	14,000		50,000		12,000	10,000	20,000		99,963	20,000	50,000	20,000	5,000
Exercise price of warrants in stock issuance					$1		$1	$1		$1		$1	$1		$1				$1	$2	$1	$1	$1	$1	$1	$1	$1		$1	$1
Common stock issued for services, shares				110,000		15,000			25,000	15,000
Distribution agreement with Yontem
Skin cream units agreed to sell per month, first year minimum	1,000
Skin cream units agreed to sell per month, second year minimum	2,000
Skin cream units agreed to sell per month, third year minimum	3,000
Distibution Agreement duration	3 years
Warrants issued for March/April 2014 debenture		226,515
Exercise price of warrants issued for March/April 2014 debenture		$1
Amount of debt converted from debentures			$254,000
Shares of common stock issued from conversion of debentures			485,000

x_Commitment_Details

x. Commitment (Details) (USD $)	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitment Payment Due	$3,297	$36,258	$39,555

x_Commitment_Details_Narrative

x. Commitment (Details Narrative)	0 Months Ended	12 Months Ended
	Sep. 11, 2014	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Rental Lease commitment	26 months	26 months